Effect of creatinine clearance on patterns of toxicity in older patients receiving adjuvant chemotherapy for breast cancer

被引:25
|
作者
Hurria, A [1 ]
Hurria, A [1 ]
Brogan, K [1 ]
Panageas, KS [1 ]
Pearce, C [1 ]
Norton, L [1 ]
Jakubowski, A [1 ]
Howard, J [1 ]
Hudis, C [1 ]
机构
[1] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
关键词
D O I
10.2165/00002512-200522090-00007
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
Objective: A number of age-related physiological changes contribute to an increased risk of toxicity of cancer chemotherapy in the elderly. One of the most important of these changes is the progressive decline in renal function with aging. We sought to determine the association between calculated creatinine clearance (CLCR) and grade 3 or 4 toxicities during adjuvant chemotherapy in women >= 65 years of age with breast cancer. Design and methods: We identified 1405 patients >= 65 years of age who had been treated for primary invasive breast cancer at Memorial Sloan-Kettering Cancer Center between January 1998 and December 2000. Patients were included in this analysis if they had stage I-III breast cancer and had received adjuvant chemotherapy. Patients were excluded if they had a prior history of breast cancer or chemotherapy, or had no baseline creatinine value available for review. Results: The 126 patients who met our criteria had received either cyclophosphamide, methotrexate and fluorouracil (CMF) [n = 65, mean age 7 1, range 65-78] or an anthracycline-based regimen (n = 61, mean age 69, range 65-79). The majority of patients (97%) had a normal creatinine. CLCR, as calculated by the Cockcroft-Gault and Jeliffe formulas, decreased with increasing age (increased age associated with decreased Cockcroft-Gault [p = 0.02]; increased age associated with decreased Jeliffe [p < 0.01]). In multivariate analysis, after controlling for age and co-morbidity, a CLCR <50 mL/min by the Cockcroft-Gault formula was associated with an increased risk of fever and neutropenia (odds ratio [OR] 3.60; 95% CI 1.00, 12.94; p = 0.05) and a CLCR <50 mL/min by the Jeliffe formula was associated with a trend towards an increased risk of fever and neutropenia (OR 3.30; 95% CI 0.91, 12.33; p = 0.07), grade 3 or 4 haematological toxicity (OR 2.43; 95% CI 0.90, 6.55; p = 0.08), and need for erythropoietin (OR 4.15; 95% CI 0.81, 2.99; p = 0.09). An increase in creatinine (as a continuous variable) was associated with a trend towards an increased risk of grade 3 or 4 haematological toxicity (OR 5.81; 95% CI 0.96, 35.33; p = 0.06). Conclusions: In this cohort of older breast cancer patients, a decreased CLCR and increased creatinine was associated with an increased risk of fever and neutropenia or haematological toxicity. CLCR should be considered when determining chemotherapy dosage in the elderly.
引用
收藏
页码:785 / 791
页数:7
相关论文
共 50 条
  • [21] Incidence of anaemia in breast cancer patients receiving adjuvant chemotherapy
    Denison, U
    Baumann, J
    Peters-Engl, C
    Samonigg, H
    Krippl, P
    Lang, A
    Obermair, A
    Wagner, H
    Sevelda, P
    BREAST CANCER RESEARCH AND TREATMENT, 2003, 79 (03) : 347 - 353
  • [22] Cognitive Function in Breast Cancer Patients Receiving Adjuvant Chemotherapy
    Chung, Kyung Hae
    Chung, Bok Yae
    Kim, Gyung Duck
    Byun, Hye Sun
    Choi, Eun Hee
    Cho, Eun Jung
    ASIAN ONCOLOGY NURSING, 2012, 12 (01) : 1 - 11
  • [23] Melatonin effect on sleep disorders in breast cancer patients receiving adjuvant chemotherapy.
    Shahrasbi, Abdolali
    Einei, Nasrin
    Esfandbod, Mohsen
    Derakhshan, Kamran
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [24] Dose intensity and hematologic toxicity in older breast cancer patients receiving systemic chemotherapy.
    Shayne, M.
    Culakova, E.
    Wolff, D. A.
    Poniewierski, M. S.
    Lyman, G. H.
    BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 : S281 - S282
  • [25] Functional Decline and Resilience in Older Women Receiving Adjuvant Chemotherapy for Breast Cancer
    Hurria, Arti
    Soto-Perez-de-Celis, Enrique
    Allred, Jacob B.
    Cohen, Harvey Jay
    Arsenyan, Anait
    Ballman, Karla
    Le-Rademacher, Jennifer
    Jatoi, Aminah
    Filo, Julie
    Mandelblatt, Jeanne
    Lafky, Jacqueline M.
    Kimmick, Gretchen
    Klepin, Heidi D.
    Freedman, Rachel A.
    Burstein, Harold
    Gralow, Julie
    Wolff, Antonio C.
    Magrinat, Gustav
    Barginear, Myra
    Muss, Hyman
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2019, 67 (05) : 920 - 927
  • [26] Patterns of fatigue and effect of exercise in breast cancer patients receiving chemotherapy.
    Wu, Horng-Shiuann
    Dodd, Marylin
    Cho, Maria
    ONCOLOGY NURSING FORUM, 2007, 34 (02) : 561 - 561
  • [27] Cognitive function of older patients receiving adjuvant chemotherapy for breast cancer: A pilot prospective longitudinal study
    Hurria, Arti
    Rosen, Carol
    Hudis, Clifford
    Zuckerman, Enid
    Panageas, Katherine S.
    Lachs, Mark S.
    Witmer, Matthew
    van Gorp, Wilfred G.
    Fornier, Monica
    D'Andrea, Gabriella
    Moasser, Mark
    Dang, Chau
    Van Poznak, Catherine
    Hurria, Anju
    Holland, Jimmie
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2006, 54 (06) : 925 - 931
  • [28] Different adjuvant chemotherapy regimens in older breast cancer patients?
    Wildiers, H.
    Brain, E.
    ANNALS OF ONCOLOGY, 2015, 26 (04) : 613 - 615
  • [29] Effect of obesity on the toxicity profile of patients with breast cancer treated with adjuvant chemotherapy.
    Srinivasalu, Vijay Kumar
    George, Annu Susan
    Philip, Arun
    Kotne, Sanketh
    Bamroo, Sahil
    Vijaykumar, D. K.
    Pillai, Ranjini
    Beena, K.
    Jose, Wesley M.
    Pavithran, Keechilat
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [30] Voice of cancer patients: Analysis of concerns of patients receiving adjuvant chemotherapy for breast cancer
    Aggarwal, S.
    Liu, M.
    Sharma, R.
    Gupta, A.
    Singh, D.
    Sharma, R.
    Yang, F.
    Basak, A.
    Aggarwal, A.
    CANCER RESEARCH, 2016, 76